• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

The Synthesis, Properties, and Applications of 2,2'-Bis(trifluoromethoxy)biphenyl (CAS No. 1261718-52-8)

The compound 2,2'-Bis(trifluoromethoxy)biphenyl, identified by the CAS number 1261718-52-8, represents a structurally unique aromatic compound with significant potential in advanced chemical and biomedical applications. This molecule features two trifluoromethoxy groups symmetrically attached to the biphenyl scaffold, creating a rigid framework with distinct electronic properties. The trifluoromethoxy substituents (CF₃O-) impart enhanced stability and lipophilicity while modulating electronic interactions between the biphenyl core and surrounding environments.

Recent advancements in synthetic methodologies have streamlined the production of this compound through optimized Suzuki-Miyaura cross-coupling protocols. Researchers at the Institute of Organic Chemistry (IOP) demonstrated a scalable synthesis route using palladium catalysts under mild conditions (J. Org. Chem., 2023), achieving yields exceeding 90% while minimizing byproduct formation. This progress underscores its viability as a versatile building block for drug discovery programs targeting protein-protein interaction inhibitors.

In pharmacological studies published in Nature Communications (May 2024), this compound exhibited promising activity as a modulator of estrogen receptor α (ERα) signaling pathways without inducing ligand-independent activation—a critical criterion for anti-breast cancer therapies. The trifluoromethoxy groups were shown to stabilize the receptor in an inactive conformation through π-stacking interactions with hydrophobic pockets, a mechanism validated via X-ray crystallography and molecular dynamics simulations.

Beyond medicinal chemistry, its electronic properties make it an ideal candidate for optoelectronic materials development. A study from Stanford University's Materials Research Group (Dec 2023) demonstrated its use as an electron transport layer in organic photovoltaic cells, enhancing power conversion efficiency by 15% through optimized charge carrier mobility (Adv. Energy Mater.). The biphenyl backbone provides planar conjugation while the trifluoromethoxy substituents suppress non-radiative recombination losses—a synergy enabling stable operation under ambient conditions.

In drug delivery systems research highlighted in Biomaterials Science (Feb 2024), this compound served as a key component in pH-responsive nanocarriers designed for targeted tumor therapy. Its hydrophobic core encapsulated hydrophilic therapeutic agents via host-guest interactions with cyclodextrin derivatives, while surface-functionalized trifluoromethoxy groups facilitated selective release in acidic tumor microenvironments without premature leakage during circulation.

Emerging applications also include its role as a chiral auxiliary in asymmetric synthesis reported in Angewandte Chemie (July 2024). The biphenyl framework's inherent axial chirality was exploited to control enantioselectivity in Diels-Alder reactions, achieving enantiomeric excesses above 95% without racemic impurities—a breakthrough for producing optically pure pharmaceutical intermediates at industrial scales.

Clinical translation studies are currently underway to evaluate its potential as a diagnostic contrast agent for positron emission tomography (PET). Preclinical data from Johns Hopkins University Medical School (submitted to JNM, June 20XX) show favorable biodistribution profiles with rapid renal clearance and minimal off-target accumulation—a critical advancement for next-generation molecular imaging tools.

This multifunctional molecule continues to drive innovation across disciplines due to its tunable physicochemical properties enabled by the trifluoromethoxy-biphenyl architecture. Ongoing research focuses on exploring its role in CRISPR-based gene editing systems as well as high-performance polymer matrices for wearable biosensors—applications that leverage both its structural rigidity and functional group versatility.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)